TAGLN2 and ovarian neoplasm: Interestingly, PD-1 blockade did not boost the therapeutic effects of CER-TAGLN2 T cells, leading the authors to conclude that TAGLN2 silencing impaired the ability of CER T cells to control advanced ovarian tumors.